secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-09-09T23:59:59+00:00
Accession:  0001708599-25-000108
Event type: debt
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics Secures Up to $20M in Convertible Note for Parkinson's Trial
--------------------------------------------------------------------------------

- Unsecured convertible note up to $20M in five tranches tied to clinical milestones; first $5M available by Oct 1, 2025.
- Convertible at $5.18/share (9/8 close), 10% annual interest payable quarterly after first year, 5-yr maturity.
- Each tranche carries 100% warrant coverage at $5.44/share; warrants expire 60 days after first Cohort 2 dose or Sept 30, 2026.
- Proceeds to advance SER-252 Phase 1b registrational trial for advanced Parkinson's under 505(b)(2) NDA path.
- IND submission planned Q4 2025; dosing in Australia Q4 2025 and U.S. initiation Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000108/0001708599-25-000108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000108/ser-20250909.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer